ArticleTheranostics2020
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 187 citations in OpenAlex.
- Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.Journal for immunotherapy of cancer · 2021Trial
- CCL5 hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.Cancer research · 2026Article
- Decoding the dual roles of monocytes in tumor immunity: from immunosurveillance to immune evasion.Frontiers in immunology · 2026Review
- Research Progress of M6A Methylation Modification in Immunotherapy of Colorectal Cancer.Current cancer drug targets · 2026Review
- Integration of single cell and bulk transcriptomes identifies T cell stress subtypes in LUAD.Discover oncology · 2025Article
- Unveiling the mechanisms of CEBPD-orchestrated TAM polarization through RGS2/PAR2 pathway and its impact on ICB efficacy in clear cell renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bladder cancer biomarker analysis and drugtarget prediction based on pyroptosis-related genes.Discover oncology · 2025Article
- M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.European journal of medical research · 2024Article
- N6-methyladenosine methylation regulates the tumor microenvironment of Epstein-Barr virus-associated gastric cancer.World journal of gastrointestinal oncology · 2024Article
- Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.BMC cancer · 2024Article
- Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.Nature communications · 2024Article
- Article
- GDF10 and IDO1 as a thyroid cancer prognostic biomarker associated with immune infiltration.Heliyon · 2024Article
- PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.NPJ precision oncology · 2024Article
- Identification of a novel immunogenic death-associated model for predicting the immune microenvironment in lung adenocarcinoma from single-cell and Bulk transcriptomes.Journal of Cancer · 2024Article
- Deciphering the immune-metabolic nexus in sepsis: a single-cell sequencing analysis of neutrophil heterogeneity and risk stratification.Frontiers in immunology · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-checkpoint blockades (ICBs) have been routinely implemented to treat metastatic urothelial cancer (mUC), whereas robust biomarkers are urgently warranted. Herein, we explored latent promising biomarkers based on 348 pretreatment mUC samples from IMvigor210.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.